Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.21 USD

28.21
21,900,969

-0.50 (-1.74%)

Updated Aug 16, 2024 11:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Brian Bolan headshot

The Week Ahead In One Click

by Brian Bolan

A look at the important economic data and earnings that are headed your way this week.

    Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

    by Zacks Equity Research

    Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.

      Should You Buy Pfizer (PFE) Ahead of Earnings?

      by Zacks Equity Research

      Pfizer (PFE) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

        Arpita Dutt headshot

        Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

        by Arpita Dutt

        Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

          Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

          by Zacks Equity Research

          Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

            Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?

            by Zacks Equity Research

            Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.

              Sweta Killa headshot

              Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?

              by Sweta Killa

              Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.

                AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

                by Zacks Equity Research

                AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.

                  Is J&J's Pharma Sales Slowdown a Warning for Other Players?

                  by Zacks Equity Research

                  Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.

                    Sweta Killa headshot

                    Lackluster J&J Q1 Pushes Healthcare ETFs Down

                    by Sweta Killa

                    Johnson & Johnson continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales.

                      Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report?

                      by Zacks Equity Research

                      Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                        Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion

                        by Zacks Equity Research

                        Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).

                          J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down

                          by Zacks Equity Research

                          Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.

                            Arpita Dutt headshot

                            Did Pharma & Biotech M&As Pick Pace in Q1?

                            by Arpita Dutt

                            Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.

                              Roche's Hemophilia A Drug Positive in Second Phase III Study

                              by Zacks Equity Research

                              Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

                                Arpita Dutt headshot

                                5 Drug Stocks That Could Be Big Winners this Earnings Season

                                by Arpita Dutt

                                Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.

                                  Roche Launches Antibody Test to Diagnose Prostate Cancer

                                  by Zacks Equity Research

                                  Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.

                                    J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

                                    by Zacks Equity Research

                                    We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

                                      Aerie Reports Positive Data on Ophthalmic Drug Rhopressa

                                      by Zacks Equity Research

                                      Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.

                                        Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint

                                        by Zacks Equity Research

                                        Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.

                                          Swarup Gupta headshot

                                          Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz

                                          by Swarup Gupta

                                          The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.

                                            Allergan (AGN) Presents Mixed Depression Data on Botox

                                            by Zacks Equity Research

                                            Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

                                              Paratek (PRTK) Stock Continues to Rise on Positive Results

                                              by Zacks Equity Research

                                              Paratek Pharmaceuticals, Inc.'s (PRTK) shares are up more than 22% since it announced positive results from a phase III study of its lead pipeline candidate

                                                Roche Announces Positive Data on Lung Cancer Drug Alecensa

                                                by Zacks Equity Research

                                                Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.

                                                  Madeleine Johnson headshot

                                                  Mylan's EpiPen Recall Expanded to U.S.

                                                  by Madeleine Johnson

                                                  On Monday, Mylan NV???s (MYL) manufacturing partner Meridian Medical Technologies announced that it will expand its voluntary recall of the EpiPen to the United States after discussing with the Food and Drug Administration (FDA).